Literature DB >> 15580312

Alternative phospholipase D/mTOR survival signal in human breast cancer cells.

Yuhong Chen1, Vanessa Rodrik, David A Foster.   

Abstract

Cancer cells generate survival signals to suppress default apoptotic programs that protect from cancer. Phosphatidylinositol-3-kinase (PI3K) generates a survival signal that is frequently dysregulated in human cancers. Phospholipase D (PLD) has also been implicated in signals that promote survival. One of the targets of PLD signaling is mTOR (mammalian target of rapamycin), a critical regulator of cell cycle progression and cell growth. We report here that elevated PLD activity in the MDA-MB-231 human breast cancer cell line generates an mTOR-dependent survival signal that is independent of PI3K. In contrast, MDA-MB-435S breast cancer cells, which have very low levels of PLD activity, are dependent on PI3K for survival signals. The data presented here identify an alternative survival signal that is dependent on PLD and mTOR and is active in a breast cancer cell line where the PI3K survival pathway is not active.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580312     DOI: 10.1038/sj.onc.1208099

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Authors:  Paige Yellen; Mahesh Saqcena; Darin Salloum; Jiangnan Feng; Angela Preda; Limei Xu; Vanessa Rodrik-Outmezguine; David A Foster
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Authors:  Robert R Lavieri; Sarah A Scott; Paige E Selvy; Kwangho Kim; Satyawan Jadhav; Ryan D Morrison; J Scott Daniels; H Alex Brown; Craig W Lindsley
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

3.  A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.

Authors:  Karen M Henkels; Hong-Juan Peng; Kathleen Frondorf; Julian Gomez-Cambronero
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

4.  Rapamycin Protects Spiral Ganglion Neurons from Gentamicin-Induced Degeneration In Vitro.

Authors:  Shasha Guo; Nana Xu; Peng Chen; Ying Liu; Xiaofei Qi; Sheng Liu; Cuixian Li; Jie Tang
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-24

Review 5.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

Review 6.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

7.  Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.

Authors:  Vanessa Rodrik; Yang Zheng; Faith Harrow; Yuhong Chen; David A Foster
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 8.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

9.  Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway.

Authors:  Maoxi Liu; Zhongxue Fu; Xingye Wu; Kunli Du; Shouru Zhang; Li Zeng
Journal:  Tumour Biol       Date:  2015-11-27

10.  Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.

Authors:  Onica Le Gendre; Ayisha Sookdeo; Stephie-Anne Duliepre; Matthew Utter; Maria Frias; David A Foster
Journal:  Mol Cancer Res       Date:  2013-02-26       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.